Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo

The BCR/ABL tyrosine kinase promotes leukemogenesis through activation of several targets that include the phosphoinositide 3-kinase (PI3K). Tyrosine kinase inhibitors (TKIs), which target BCR/ABL, induce striking clinical responses. However, therapy with TKIs is associated with limitations such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuster, K, Zheng, J, Arbini, A A, Zhang, C C, Scaglioni, P P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255254/
https://www.ncbi.nlm.nih.gov/pubmed/22829195
http://dx.doi.org/10.1038/bcj.2011.30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255254/
https://www.ncbi.nlm.nih.gov/pubmed/22829195
http://dx.doi.org/10.1038/bcj.2011.30

Ejemplares similares